Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Other Non Operating Income (2016 - 2026)

Insight Molecular Diagnostics' Other Non Operating Income history spans 6 years, with the latest figure at $506000.0 for Q4 2025.

  • On a quarterly basis, Other Non Operating Income rose 246.58% to $506000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.0 million, a 118.83% increase, with the full-year FY2025 number at $1.0 million, up 118.83% from a year prior.
  • Other Non Operating Income hit $506000.0 in Q4 2025 for Insight Molecular Diagnostics, up from $223000.0 in the prior quarter.
  • Over the last five years, Other Non Operating Income for IMDX hit a ceiling of $506000.0 in Q4 2025 and a floor of -$1.2 million in Q4 2021.
  • Historically, Other Non Operating Income has averaged $28550.0 across 5 years, with a median of $86000.0 in 2022.
  • Biggest five-year swings in Other Non Operating Income: crashed 29350.0% in 2021 and later skyrocketed 15400.0% in 2024.
  • Tracing IMDX's Other Non Operating Income over 5 years: stood at -$1.2 million in 2021, then soared by 68.51% to -$371000.0 in 2022, then skyrocketed by 156.06% to $208000.0 in 2023, then fell by 29.81% to $146000.0 in 2024, then soared by 246.58% to $506000.0 in 2025.
  • Business Quant data shows Other Non Operating Income for IMDX at $506000.0 in Q4 2025, $223000.0 in Q3 2025, and $125000.0 in Q2 2025.